Traws Pharma Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing antiviral and oncology drug candidates. The company generates no product revenue, funding operations through equity financings, including an April 2026 financing that raised up to $60.0 million in aggregate gross proceeds. Its pipeline centers on two programs: ratutrelvir (TRX01), an oral SARS-CoV-2 main protease inhibitor targeting COVID-19 without ritonavir co-administration, and narazaciclib, an oral multi-targeted CDK4-plus kinase inhibitor in development for low-grade endometrioid endometrial cancer and other cancers. Narazaciclib is also being developed in greater China under a 2017 license agreement with HanX. CEO Iain Dukes, D.Phil. assumed the permanent title on October 1, 2025, with Charles Parker serving as CFO as of the same date. The company operates at a deficit, carries deferred revenue on its balance sheet, and relies on CROs and third-party manufacturers for development activities, per the 10-K filed April 15, 2026.

Revenue model

No commercial product revenue as of the fiscal year ended December 31, 2025. Operations are funded through equity financings and warrant issuances. Deferred revenue appears on the balance sheet, likely related to the HanX license agreement for narazaciclib in greater China.

Products and services

Ratutrelvir (TRX01): oral SARS-CoV-2 main protease (3CL protease) inhibitor targeting COVID-19 replication, intended for use without ritonavir. Narazaciclib: oral multi-targeted CDK4-plus kinase inhibitor targeting CDK4, CDK6, CDK9, ARK5, CSF1R, and FLT3, in development for low-grade endometrioid endometrial cancer and other cancers, including a Phase trial in Grade III/IV glioma in China sponsored by HanX.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets are infectious disease (COVID-19) and oncology (endometrial cancer, glioma, and other cancers). Development partner HanX holds the narazaciclib license for greater China.

Value-chain role

Drug developer relying on contract research organizations (CROs) and third-party manufacturers for preclinical and clinical development. Traws sponsors trials, holds IP, and seeks regulatory approvals (NDA pathway with the FDA; MHRA in the UK for a planned human challenge trial). The company has not reached the commercialization stage.

Geographic exposure

Primary development activities in the United States, with a UK human challenge trial planned pending MHRA approval. Narazaciclib development in greater China conducted and sponsored by licensee HanX.

Competitors

Roche (oseltamivir/Tamiflu, zanamivir/Relenza, baloxavir marboxil/Xofluza), GSK (zanamivir/Relenza), BioCryst (peramivir/Rapivab), Gilead (remdesivir), Pfizer (nirmatrelvir + ritonavir; palbociclib), Merck (molnupiravir), Novartis (ribociclib), Eli Lilly (abemaciclib)

Source: SEC 10-K, filed 2026-04-15

Industry: Pharmaceutical Preparations Peers: Acer Therapeutics Inc. Biofrontera Inc Context Therapeutics Inc Avenir Wellness Solutions, Inc. CalciMedica Inc Johnson & Johnson LANNETT CO INC MJ Holdings, Inc. Provectus Biopharmaceuticals Inc